In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitors Considerations in therapy selection for previously treated CLL Novel strategies for treating CLL   Presenters: Danielle M. Brander, MD Assistant Professor of Medicine Division of Hematologic Mal ..read more

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:  Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2 FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations bas ..read more

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatment of patients with HER2-low advanced breast cancer Role of TROP-2–targeted therapies Management of ADC-associated adverse events to optimize treatment outcomes ADCs on the horizon for patients with advanced breast cancer Link to full prog ..read more

The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer.  Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational ..read more

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab The HER2xHER3 bispecific antibody zenocutuzumab The HER3-targeted antibody–drug conjugate SHR-A2009  Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate At ..read more

This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc.  Link to full program, including a downloadable highlights slideset: https://bit.ly ..read more

In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including: Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or placebo maintenance for 2 years in patients with measurable stage III/IVA, stage IVB, or recurrent endometrial cancer.  Phase III ENGOT-EN6/GOG-3031/RUBY trial of carboplatin and paclitaxel with or without dostarlimab followed by dostarlimab or pla ..read more

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including: Navitoclax (BCL-XL/BCL-2 inhibitor) Pelabresib (BET inhibitor) Imetelstat (telomerase inhibitor) Luspatercept (erythroid maturation agent) Additional strategies Presenter:   Jacqueline S. Garcia, MD Assistant Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts Link to the full program here. https://bit.ly/47z8WCV     ..read more

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:  SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL  TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL  ZU ..read more

In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including: Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline t ..read more